In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration’s ...

Adcetris is also indicated as monotherapy or in combination with chemotherapy for the treatment of certain types of classical Hodgkin lymphoma, anaplastic large cell lymphoma and peripheral T-cell ...

NICE has ruled that Takeda’s Hodgkin’s lymphoma treatment Adcetris should no longer be funded on the NHS, saying there isn’t enough evidence to support its use. The treatment is a ‘legacy ...

Ma­jor drug­mak­ers are plan­ning to meet with Pres­i­dent Don­ald Trump next week at the White House as part of the in­dus­try’s ef­fort to work with … ...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible for autologous stem cell transplantation. The FDA has approved ...

Adcetris has a list price of £2,500 per 50 mg vial – equivalent to almost £48,000 for the six treatment cycles required by the average patient – but has been recommended by NICE after Takeda ...

New York: Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS (brentuximab vedotin) in ...

Feb. 13, 2025 -- The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL). LBCL is a fast-growing cancer of B ...

The approval was based on data from the ECHELON-3 trial. The US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and a ...